Here are four takeaways:
1. The analysts have a price target of $23 on K2M shares.
2. On Oct. 7, K2M shares rallied 1.38 percent, hitting $18.40.
3. Since March 7, 2016, the shares have increased 38.35 percent and are uptrending.
4. K2M shares have outperformed the S&P 500 by 30.75 percent.
More device news:
St. Jude Medical receives FDA approval, announces 1st implant of Infinity DBS system: 5 observations
Zacks downgrades Entellus Medical to ‘hold’: 4 thoughts
NIH awards RIVANNA $1.5M grant to develop anesthesia platform for orthopedic care: 3 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
